Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASSc study of rituximab in active systemic sclerosis
NL-OMON59886Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in systemic sclerosis (SSc) comparing Rituximab plus stable background therapy with Placebo plus stable background therapy (2 arms). Primary endpoints: Disease progression after 12 months, Skin progression component and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON59886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59886.